Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180157 | 0.92 | POLB (0.57) | POLBGPBAR1ALDH1A1LMNAGAA | |
| SCHEMBL4179427 | 0.92 | POLB (0.57) | POLBGPBAR1ALDH1A1LMNAGAA | |
| SCHEMBL4177341 | 0.92 | POLB (0.57) | POLBGPBAR1ALDH1A1LMNAGAA | |
| SCHEMBL4190644 | 0.83 | POLB (0.66) | POLBGPBAR1ALDH1A1LMNAGAA | |
| SCHEMBL4181758 | 0.80 | POLB (0.56) | POLBGPBAR1TSHRCYP19A1MEN1 | |
| SCHEMBL7209087 | 0.79 | GPBAR1 (0.91) | POLBGPBAR1ALDH1A1LMNATSHR | |
| SCHEMBL4184648 | 0.79 | POLB (0.57) | POLBGPBAR1TSHRCYP19A1MEN1 | |
| SCHEMBL4180062 | 0.79 | POLB (0.57) | POLBGPBAR1TSHRCYP19A1MEN1 | |
| SCHEMBL4174455 | 0.79 | POLB (0.57) | POLBGPBAR1TSHRCYP19A1MEN1 | |
| SCHEMBL7205052 | 0.78 | GPBAR1 (0.88) | GPBAR1ALDH1A1LMNATSHRMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | POLB 4819/4885GPBAR1 81/4885ALDH1A1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.